Table 1.
Selected clinical trials for EGFR-resistant NSCLC
| Drug | Target(s) | Phase | Identifier* |
|---|---|---|---|
| AZD9291 | EGFR T790M | I/II | NCT01802632 |
| PF-02341066 | MET inhibitor | ||
| PF-00299804 | PAN-HER inhibitor | I | NCT01121575 |
| BIBW 2992 | EGFR and ERBB2 | II | NCT01542437 |
| Bevacizumab | VEGF | II | NCT02139579 |
| Selumetinib | EGFR T790M | I/II | NCT02025114 |
| ASP8273 | EGFR T790M | I/II | NCT02192697 |
| MSC2156119J | MET | I/II | NCT01982955 |
| ARQ 197 | MET | II | NCT01580735 |
| Arsenic trioxide | Apoptotic pathway | I | NCT02066870 |
| AUY922 | Hsp90 | I/II | NCT01259089 |
| Everolimus | PI3K/AKT/MTOR | NCT00124280 | |
| Vorinostat-Iressa | HDAC | I | NCT02151721 |
Note:
*
Identifier from ClinicalTrials.gov.
Abbreviations: EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; VEGF, vascular endothelial growth factor; Hsp90, heat shock protein 90; PI3K, phosphatidylinositol 3-kinases; MTOR, mammalian target of rapamycin; HDAC, histone deacetylase inhibitor.